Eurosurveillance banner




Announcements
Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Edition  2008: Volume 13/ Issue 15 Article 4 Printer friendly version
Back to Table of Contents
Previous Download (pdf) Next

Eurosurveillance, Volume 13, Issue 15, 10 April 2008
Rapid communications
Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales
  1. Sexually Transmitted Bacteria Reference Laboratory, Centre for Infections, Health Protection Agency, London, the United Kingdom

Citation style for this article: Chisholm SA, Ison C. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. Euro Surveill. 2008;13(15):pii=18832. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18832
Date of submission: 10 April 2008

The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales has monitored azithromycin resistance since 2001. In 2007, high-level azithromycin resistance (MICs >256 mg/L) was identified for the first time in six isolates, all of which were the same sequence type (ST 649).

High-level azithromycin resistance has also been reported in Scotland, but it is not known if this has wider geographical dissemination. It has been recommended that gonococcal resistance to azithromycin should be monitored in regions or countries where this drug is used to treat Chlamydia trachomatis infection. Furthermore, specific anti-gonococcal therapy should always be used to treat gonorrhoea. Azithromycin is not a recommended treatment for gonorrhoea in the United Kingdom [1]. Further information on this emerging resistance can be found at http://www.hpa.org.uk/hpr/archives/2008/hpr1408.pdf and http://www.dh.gov.uk/en/Publichealth/Patientsafety/Microbiologyandinfectioncontrol/DH_075723


References

  1. Clinical effectiveness group, British Association for Sexual Health and HIV.
    National Guideline on the Diagnosis and Treatment of Gonorrhoea in Adults 2005. Available from: http://www.bashh.org/guidelines/2005/gc_final_0805.pdf


Back to Table of Contents
Previous Download (pdf) Next

Disclaimer:The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal.
The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement.

Eurosurveillance [ISSN] - ©2007-2013. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.